Initial two-drug combination for stage 2 hypertension

HTNmedium

A 56-year-old man with hyperlipidemia treated with pravastatin establishes care. He feels well, has a sedentary lifestyle, and does not use tobacco. BP is 158/97 mm Hg and BMI is 30 kg/m²; examination is otherwise unremarkable. Basic metabolic panel, complete blood count, and urinalysis are normal. Total cholesterol is 180 mg/dL and HDL 32 mg/dL. ECG shows sinus rhythm with left axis deviation. After 2 weeks of twice-daily home monitoring, his average home BP is 156/94 mm Hg. He receives counseling on a low-sodium, heart-healthy diet and regular physical activity and appears motivated. What is the most appropriate next step?

  1. A.Prescribe benazepril-amlodipineCorrect
  2. B.Reassess BP 3 months after intensive lifestyle changes
  3. C.Measure plasma renin activity and aldosterone level
  4. D.Prescribe hydrochlorothiazide

Explanation

The most appropriate next step is to prescribe a single-pill combination of benazepril and amlodipine. This patient has stage 2 hypertension confirmed by home BP monitoring (average 156/94 mm Hg), with obesity, low HDL cholesterol, and hyperlipidemia contributing to elevated cardiovascular risk. The ACC/AHA guideline recommends starting antihypertensive drug therapy together with lifestyle changes for stage 2 hypertension, and initiating two first-line agents of different classes when BP is more than 20/10 mm Hg above the target of below 130/80 mm Hg. His BP exceeds the target by about 26/14 mm Hg. Monotherapy typically lowers systolic BP by only about 10 mm Hg, so it rarely achieves control at this level, whereas initial combination therapy reaches target faster, reduces clinical inertia, and improves adherence when given as a single pill. In ACCOMPLISH, the combination of benazepril with amlodipine reduced cardiovascular events by 20% compared with benazepril plus hydrochlorothiazide in high-risk patients, making this a well-supported pairing. Hydrochlorothiazide monotherapy is a reasonable first-line agent for stage 1 hypertension or when BP is closer to target, but as a single drug it is unlikely to lower BP by the 26/14 mm Hg needed here. Chlorthalidone is also preferred over hydrochlorothiazide when a thiazide is chosen, given its longer duration of action. Screening for primary aldosteronism with plasma renin activity and aldosterone is recommended for resistant hypertension, hypokalemia, adrenal incidentaloma, sleep apnea, or early-onset hypertension, and more recent guidance broadens screening further. His normal metabolic panel and uncomplicated presentation make this a lower priority than starting treatment, although it could be considered later. Reassessing BP after 3 months of lifestyle changes alone is appropriate for stage 1 hypertension with low estimated cardiovascular risk. For confirmed stage 2 hypertension, delaying drug therapy prolongs exposure to elevated BP without benefit; lifestyle measures should accompany, not replace, medication.

Why each option

A.
Correct. Home BP 156/94 mm Hg exceeds the 130/80 target by more than 20/10 mm Hg, warranting initial two-drug therapy, supported by ACCOMPLISH for this pairing.
B.
Lifestyle-only trials suit low-risk stage 1 hypertension; confirmed stage 2 hypertension requires drug therapy started alongside lifestyle changes, not delayed.
C.
Aldosteronism screening targets resistant hypertension, hypokalemia, or adrenal incidentaloma; with a normal metabolic panel, starting therapy takes priority over testing.
D.
Thiazide monotherapy suits stage 1 hypertension; a single agent rarely lowers BP by the 26/14 mm Hg needed, and chlorthalidone is the preferred thiazide.

Reference: Whelton PK, Hypertension 2018 (ACC/AHA guideline for high blood pressure in adults); Jamerson K, N Engl J Med 2008 (ACCOMPLISH)

This is one of 1,100 questions in the MedBoardSA nephrology bank, with timed test mode, tutor mode, and progress tracking by topic.

Practise the full bank

More HTN questions

Browse other topics